While Recommendation from the Japanese Society of Nephrology regarding the optimal application of SGLT2 inhibitors in CKD management [5], evidence supporting their efficacy in ADPKD remains scarce. Here, SLC5A2 is linked to autosomal dominant polycystic kidney disease.